Where Will Applied Therapeutics Inc (APLT) Stock Go Next After It Is Lower By 5.76% in a Week?

Overall market sentiment has been high on Applied Therapeutics Inc (APLT) stock lately. APLT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Applied Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on APLT!

See Full APLT Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With APLT Stock Today?

Applied Therapeutics Inc (APLT) stock is lower by -6.73% while the S&P 500 is up 0.78% as of 1:55 PM on Tuesday, Oct 10. APLT is lower by -$0.16 from the previous closing price of $2.45 on volume of 372,737 shares. Over the past year the S&P 500 is up 20.96% while APLT is up 263.49%. APLT lost -$1.24 per share in the over the last 12 months. To screen for more stocks like Applied Therapeutics Inc click here.

More About Applied Therapeutics Inc

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Click Here to get the full Stock Report for Applied Therapeutics Inc stock.